Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.

From being little known to sought after by millions, Pfizer’s oral antiviral Paxlovid is fast becoming the most pursued medicine in China, amid the largest outbreak of COVID-19 infections the world has yet seen.

Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.